Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
about
Cardiotoxicity in childhood cancer survivors: strategies for prevention and managementAggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicinVariation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicityModifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407Anthracyclines and the heart.Drug delivery in a tumour cord model: a computational simulationCardiovascular toxicities from systemic breast cancer therapy.A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.Cardiotoxic effects of anthracycline-taxane combinations.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesA comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesAnthracycline cardiotoxicity.Anthracycline cardiotoxicity in childhood.New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.Heart failure and chemotherapeutic agents.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Infusional chemotherapy for non-Hodgkin's lymphoma.Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.A tumor cord model for doxorubicin delivery and dose optimization in solid tumors.Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.Evaluation of the epidoxorubicin--formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model.Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple MyelomaGalectins as Molecular Targets for Therapeutic Intervention.
P2860
Q24628695-A2371A15-C57F-46EA-BDBF-96944D0D2110Q28368331-152E87DE-F244-4450-9B3A-0B485E1DF875Q33367028-FF0C7D3B-7669-4F04-9BE5-33BE735767E1Q33559419-86C52EC5-54AF-4030-AE1C-75078F1C80D3Q33613628-29B13B8E-AEE4-4140-896B-B56FA6892D9BQ33748082-3EF7B968-55D7-4AE1-B5D0-1BCA799B1CADQ34630349-006F3243-096B-4EF7-B89C-A2C6C4910447Q34997356-289CF11D-139A-4452-AC56-044054DDD337Q35194442-5316FB4B-F4C5-41EB-B194-F76AE9C6371EQ35583768-273951BE-2302-4597-9D4F-77599E0CF42AQ35753383-5BFB4C96-B25F-41BE-B514-4AB0162E2AC2Q36425761-18AC3E08-C5A3-4CC1-B2C1-9AF971566F62Q36624983-8263C67B-C09B-4388-966C-55BC0F8B75C1Q37165394-CF3366CC-6AC2-46A9-AA94-CB433552B45BQ37355919-2944A126-9095-4C93-B4D3-30E064E30E4DQ38559133-42B2EDE8-71DF-4AA4-9B40-8A45BF925F8BQ38838517-3B9BF3C6-2D1B-40E3-9DE3-D1187AD8962FQ41605392-D53C483B-6ADD-4689-A7F5-3E9ADF811F70Q42537936-7AB1D1DD-1783-46A1-B249-18CD7E3C3C89Q42542144-7DFB0356-C2A7-446C-8C05-05DDF64C007EQ43653702-19B7D0EA-EDB9-4CEC-9AA4-6968F298A202Q44115435-A4C17B2F-9BDA-4898-8716-CF1BEBC3BAF3Q44128427-2F8674D0-FC2E-4A9B-B191-D8AE97DD4B10Q54995893-A20BBDE6-35DA-4674-8A5E-3CB7B6461F81Q55014795-D6B249D6-E6B3-4604-823C-37955225CAB7Q55316400-BF0E0992-15BC-440E-BAEF-968360F9217C
P2860
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@en
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@nl
type
label
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@en
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@nl
prefLabel
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@en
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@nl
P2093
P2860
P1433
P1476
Decreased cardiac toxicity of ...... r metastatic breast carcinoma.
@en
P2093
Carrasco CH
Fraschini G
Hortobagyi GN
Montague E
P2860
P356
10.1002/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z
P407
P577
1989-01-01T00:00:00Z